AR | |
---|---|
Salts [] | |
---|---|
Fumarate | |
Molecular structure via molpic based on CDK |
Conformer [] | |
---|---|
Physical properties [] | |
---|---|
Molecular mass | 162.19 g/mol [1] |
Appearance | Crystals from benzene [1] |
Melting point | 136-138 °C [1] |
Predicted LogP | 0.8 [1] |
Structural Identifiers [] | |
---|---|
Molecular formula | C9H10N2O [1] |
IUPAC name | 5-phenyl-4,5-dihydro-1,3-oxazol-2-amine [1] |
SMILES | C1C(OC(=N1)N)C2=CC=CC=C2 [1] |
InChI | InChI=1S/C9H10N2O/c10-9-11-6-8(12-9)7-4-2-1-3-5-7/h1-5,8H,6H2,(H2,10,11) [1] |
InChIKey | SYAKTDIEAPMBAL-UHFFFAOYSA-N [1] |
Aminorex
Aminorex (also known as Aminoxafen, Aminoxaphen, Apiquel, 2-Oxazolamine, 4,5-dihydro-5-phenyl-, 2-Amino-5-phenyl-2-oxazoline, McN-742, Aminorexum, 5-Phenyl-4,5-dihydro-1,3-oxazol-2-amine, 4,5-Dihydro-5-phenyl-2-oxazolamine or 636-641-3) is a stimulant substance of the aminorex class.
Chemistry
Salts []
Aminorex is typically found in the form of its fumarate salt.
Stereochemistry []
Aminorex is a racemic mixture of the optical stereoisomers
Stereoisomers |
---|
Subjective effects
Legal status
- Brazil: Aminorex is a B2 substance.[3]
- Canada: Aminorex is a Schedule III substance.
- United Kingdom: Aminorex is a Class C substance.
- United States: Aminorex is a Schedule I under the "Controlled Substances Act (CSA)".
- Germany: Aminorex is a Anlage II substance.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 16630, Aminorex. Accessed July 13, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/16630
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Aminorex. UNII: 2SH16612I9. Global Substance Registration System. Accessed July 13, 2025. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2SH16612I9
Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed July 13, 2025. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992